Mark Carlton

Mark gained his PhD from the University of Cambridge in the laboratories where the use of embryonic stem cells in mammalian functional genomics was pioneered by Professor Sir Martin Evans (Nobel prize for Medicine 2007). Mark has over 20 years experience of research and management in this area and was a co-founder of Paradigm Therapeutics Ltd in 1999 and Paradigm Therapeutics Singapore in 2003. Mark drove the company's drug discovery, operational and corporate growth. Paradigm established an industrialized mouse knockout, phenotyping capability that was integrated to a Drug Discovery engine which together attracted Takeda to firstly partner with Paradigm in the CNS area, then to full acquisition by Takeda. Mark was appointed President and CSO of Takeda Cambridge and Takeda Singapore in March 2007.

Mark Carlton is the CSO & Co-Founder at Cerevance, based in Europe. With a background in Biotechnology, Mark Carlton has a rich history of leadership and innovation.Mark Carlton studied PhD Genetics at University of Cambridge. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.